Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says
This article was originally published in The Pink Sheet Daily
Outstanding talent and patient needs for Asians are the main reason to be in Asia, not cost, Pfizer R&D exec Mackay stressed at a Singapore press conference.
You may also be interested in...
Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers
A new multi-pharma company collaboration is intended to dramatically speed development of new combination regimens for tuberculosis, but efforts to accelerate development may be hindered by the lack of biomarkers for TB
Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years
SINGAPORE - Pfizer became the first pharma company to be accredited by the U.S.-based Association for the Accreditation of Human Research Protection Programs for its Phase I Clinical Research Unit in Singapore